Figure 4.
Kaplan-Meier survival plots for the validation cohort after analysis of LC3B and HMGB1. Metastasis-free survival (MFS) of BC patients included in the PACS04 trial after stratification of patients according to (A) cytoplasmic LC3B puncta in BC cells (>10% = positive, or<10% = negative), or (C) nuclear HMGB1 expression in breast cancer cells (>50% = positive, or <50% = negative). Breast cancer-specific survival (BCSS) in the PACS04 trial according to (B) cytoplasmic LC3B puncta and (D) nuclear HMGB1 expression. P values were calculated using the log-rank test.